title: Antiretroviral therapy: dolutegravir sets SAIL(ING).
authors.affiliation: The Kirby Institute for infection and immunity in society, University of New South Wales, Sydney, NSW 2052, Australia. mboyd@kirby.unsw.edu.au
authors.forename: Mark A
authors.initials: MA
authors.lastname: Boyd
authors.forename: Basil
authors.initials: B
authors.lastname: Donovan
mesh_terms: D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage*; D015497:HIV-1; D006575:Heterocyclic Compounds, 3-Ring / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D011760:Pyrrolidinones / Q000008:administration & dosage*; D000068898:Raltegravir Potassium; D000099226:Dolutegravir
chemical_list: D019428:HIV Integrase Inhibitors; D006575:Heterocyclic Compounds, 3-Ring; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D000099226:Dolutegravir